Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended 30 September 2026 (Q2 FY27, H1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results under SEBI LODR Regulations 30 and 33

Audit Opinion:

Unmodified opinion (clean) - No qualifications or modifications

Key Financial Highlights [Currency: Indian Rupees in million]:

Consolidated Results:

Quarter Ended 30 September 2026 (Q2 FY27):

  • Revenue from Operations: ₹2,173.20 million (76% YoY increase from ₹1,235.16 million in Q2 FY26)
  • Total Income: ₹2,190.74 million
  • Profit Before Tax: ₹289.40 million (112% YoY increase from ₹136.63 million)
  • Net Profit: ₹214.51 million (116% YoY increase from ₹99.17 million)
  • EPS (Basic): ₹9.17 (vs ₹4.24 in Q2 FY26)

Half Year Ended 30 September 2026 (H1 FY27):

  • Revenue from Operations: ₹3,843.75 million (60% YoY increase from ₹2,403.80 million in H1 FY26)
  • Total Income: ₹3,889.09 million
  • Profit Before Tax: ₹500.51 million (120% YoY increase from ₹227.64 million in H1 FY26)
  • Net Profit: ₹374.32 million (126% YoY increase from ₹165.68 million)
  • EPS (Basic): ₹16.00 (vs ₹7.08 in H1 FY26)

Comparative Performance:

  • Q2 FY27 vs Q2 FY26: Revenue growth of 76%, Net Profit growth of 116%
  • H1 FY27 vs H1 FY26: Revenue growth of 60%, Net Profit growth of 126%

Balance Sheet (Consolidated as at 30 September 2026):

  • Paid-up Equity Share Capital: ₹233.92 million
  • Other Equity: ₹7,912.59 million
  • Total Assets: ₹11,187.30 million

Standalone Results:

Quarter Ended 30 September 2026 (Q2 FY27):

  • Revenue from Operations: ₹2,074.84 million (79% YoY increase from ₹1,158.63 million)
  • Net Profit: ₹153.87 million (72% YoY increase from ₹89.41 million)
  • EPS (Basic): ₹6.57 (vs ₹3.82 in Q2 FY26)

Half Year Ended 30 September 2026 (H1 FY27):

  • Revenue from Operations: ₹3,541.86 million (57% YoY increase from ₹2,250.43 million)
  • Net Profit: ₹258.33 million (84% YoY increase from ₹140.74 million)
  • EPS (Basic): ₹11.04 (vs ₹6.01 in H1 FY26)

Segment-wise Performance:

The company has only one reportable business segment - specialty chemicals. Accordingly, segment disclosure is not required as per Ind AS 108 Operating Segments.

Corporate Actions:

No dividend declarations, share splits, bonus issues, buybacks, or capital structure changes were announced in this filing.

Other Significant Information:

Entities included in consolidation:

  • Tatva Chintan Pharma Chem Limited (Holding Company)
  • Tatva Chintan USA Inc. (Wholly Owned Subsidiary)
  • Tatva Chintan Europe B.V. (Wholly Owned Subsidiary)

Cash Flow Analysis (Consolidated H1 FY27):

  • Net cash used in operating activities: ₹(36.76) million
  • Net cash used in investing activities: ₹(313.36) million
  • Net cash from financing activities: ₹399.64 million
  • Net decrease in cash: ₹49.52 million
  • Cash and cash equivalents at end: ₹106.79 million

Exceptional Items:

Q1 FY26 included exceptional items of ₹13.18 million, but no exceptional items in Q2 FY27